Overview

RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer

Status:
Active, not recruiting

Trial end date:
2024-03-31

Target enrollment:

Participant gender:

Summary

This Phase 3 study aims to find out whether RRx-001 + platinum chemotherapy is more effective than platinum chemotherapy alone in 3rd line or beyond small cell cancer.

Phase:

Phase 3

Details

Lead Sponsor:

EpicentRx, Inc.

Treatments:

Carboplatin
Cisplatin
Etoposide
Etoposide phosphate